| Primary |
| Drug Use For Unknown Indication |
56.2% |
| Hyperkalaemia |
20.7% |
| Product Used For Unknown Indication |
3.9% |
| Hypertension |
2.5% |
| Diabetes Mellitus |
2.0% |
| Dialysis |
2.0% |
| Epilepsy |
1.5% |
| Thrombosis Prophylaxis |
1.5% |
| Blood Potassium Increased |
1.0% |
| Diabetes Insipidus |
1.0% |
| Hypertriglyceridaemia |
1.0% |
| Hyperuricaemia |
1.0% |
| Liposarcoma |
1.0% |
| Premedication |
1.0% |
| Type 1 Diabetes Mellitus |
1.0% |
| Type 2 Diabetes Mellitus |
1.0% |
| Arthralgia |
0.5% |
| Atrial Fibrillation |
0.5% |
| Atrial Flutter |
0.5% |
| Bone Pain |
0.5% |
|
| Hypokalaemia |
13.0% |
| Intravascular Haemolysis |
8.7% |
| Haemolysis |
6.5% |
| Large Intestine Perforation |
6.5% |
| No Adverse Event |
6.5% |
| Rectal Stenosis |
6.5% |
| Rhabdomyolysis |
6.5% |
| Tubulointerstitial Nephritis |
6.5% |
| Ventricular Tachycardia |
6.5% |
| Drug Prescribing Error |
4.3% |
| Gastrointestinal Necrosis |
4.3% |
| Rash Maculo-papular |
4.3% |
| Thrombocytopenia |
4.3% |
| Anaemia |
2.2% |
| Angioedema |
2.2% |
| Aspiration |
2.2% |
| Bicytopenia |
2.2% |
| Bladder Cancer |
2.2% |
| Bladder Transitional Cell Carcinoma Stage Ii |
2.2% |
| Bradycardia |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
29.1% |
| Drug Use For Unknown Indication |
19.1% |
| Type 2 Diabetes Mellitus |
8.5% |
| Congestive Cardiomyopathy |
7.5% |
| Hyperkalaemia |
5.6% |
| Hypertension |
4.3% |
| Diabetes Mellitus |
4.2% |
| Hyperphosphataemia |
4.0% |
| Hyperuricaemia |
2.7% |
| Diabetes Insipidus |
2.5% |
| Hypertriglyceridaemia |
2.3% |
| Essential Hypertension |
2.0% |
| Ill-defined Disorder |
2.0% |
| Renal Transplant |
1.3% |
| Epilepsy |
1.2% |
| Duodenitis |
0.8% |
| Pain |
0.8% |
| Proteinuria |
0.8% |
| Atrial Fibrillation |
0.7% |
| Cardiac Disorder |
0.7% |
|
| Stillbirth |
14.0% |
| Intra-uterine Death |
13.0% |
| Hypokalaemia |
6.0% |
| Intravascular Haemolysis |
6.0% |
| Thrombocytopenia |
6.0% |
| Bladder Cancer |
5.0% |
| Condition Aggravated |
5.0% |
| Lung Disorder |
5.0% |
| Vomiting |
5.0% |
| Anaemia |
4.0% |
| Foetal Death |
4.0% |
| Hypertension |
4.0% |
| Leukocytoclastic Vasculitis |
4.0% |
| Nephropathy |
4.0% |
| Colitis |
3.0% |
| Dizziness |
3.0% |
| Weight Decreased |
3.0% |
| Bladder Transitional Cell Carcinoma Stage Ii |
2.0% |
| Cardiomyopathy |
2.0% |
| Drug Exposure During Pregnancy |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.1% |
| Drug Use For Unknown Indication |
27.1% |
| Hypertension |
6.1% |
| Multiple Myeloma |
2.5% |
| Prophylaxis |
2.5% |
| Nuclear Magnetic Resonance Imaging |
2.5% |
| Hyperkalaemia |
2.2% |
| Diabetes Mellitus |
2.0% |
| Pain |
1.8% |
| Anaemia |
1.8% |
| Renal Failure Chronic |
1.8% |
| Angiogram |
1.4% |
| Thrombosis Prophylaxis |
1.3% |
| Diarrhoea |
1.3% |
| Renal Transplant |
1.3% |
| Infection |
1.2% |
| Depression |
1.1% |
| Hepatic Neoplasm Malignant |
1.0% |
| Hyperphosphataemia |
1.0% |
| Therapeutic Embolisation |
1.0% |
|
| Vomiting |
14.5% |
| Renal Failure |
9.5% |
| Renal Failure Acute |
8.6% |
| Weight Decreased |
7.9% |
| Pyrexia |
6.6% |
| Pleural Effusion |
5.6% |
| Renal Failure Chronic |
4.9% |
| Thrombocytopenia |
4.6% |
| Renal Impairment |
3.9% |
| Sepsis |
3.9% |
| Death |
3.3% |
| Rectal Haemorrhage |
3.3% |
| Aplastic Anaemia |
3.0% |
| Cytolytic Hepatitis |
3.0% |
| Hyperkalaemia |
3.0% |
| Orthostatic Hypotension |
3.0% |
| Urinary Tract Infection |
3.0% |
| Weight Increased |
3.0% |
| White Blood Cell Count Increased |
3.0% |
| Neutropenia |
2.6% |
|
| Interacting |
| Drug Use For Unknown Indication |
30.0% |
| Arthralgia |
20.0% |
| Nephrotic Syndrome |
20.0% |
| Congenital Hand Malformation |
10.0% |
| Gouty Tophus |
10.0% |
| Grand Mal Convulsion |
10.0% |
|
| Vomiting |
66.7% |
| Drug Level Decreased |
33.3% |
|
